ALK IHC companion diagnostic - Ventana Medical Systems

Drug Profile

ALK IHC companion diagnostic - Ventana Medical Systems

Alternative Names: Alectinib companion diagnostic - Ventana Medical Systems; ALK gene rearrangement diagnostic - Ventana MEdical Systems; Crizotinib companion diagnostic - Ventana Medical Systems; RG 7853 companion diagnostic - Ventana Medical Systems; VENTANA ALK (D5F3) CDx Assay; VENTANA ALK IHC diagnostic test

Latest Information Update: 05 Jun 2017

Price : $50

At a glance

  • Originator Ventana Medical Systems
  • Developer Roche; Ventana Medical Systems
  • Class Diagnostic agents; Monoclonal antibody diagnostics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 01 Jun 2017 The US FDA approves VENTANA ALK (D5F3) CDx Assay as a companion diagnostic for ceritinib in Non-small cell lung cancer (Diagnosis; ALK-positive) in USA
  • 07 Nov 2016 The US FDA approves ALK IHC companion diagnostic for crizotinib for use on the VENTANA BenchMark ULTRA automated slide stainer in USA
  • 15 Jun 2015 Registered for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top